Real-World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant-Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada. (PubMed, EJHaem) - Oct 18, 2026 - "Most patients received bendamustine and rituximab in 1L (76.7%) and ibrutinib in second-line (2L; 73.2%). Poor real-world clinical outcomes support the need for additional 1L and R/R therapies for MCL management for an ASCT-ineligible population. The authors have confirmed clinical trial registration is not needed for this submission."
HEOR • Journal • Real-world evidence • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation
|
|
Anca Prica; Anisia Wong; Mackenzie A Hamilton; Sandra Thibault; Soo Jin Seung; Sydney George
|